MedPath

A multicentric, double blind, randomized, comparative Phase II b study of the efficacy of a wound healing solution in patients with diabetic foot ulcer

Conditions
diabetic foot ulcer
MedDRA version: 14.0Level: LLTClassification code 10012664Term: Diabetic foot ulcerSystem Organ Class: 10027433 - Metabolism and nutrition disorders
Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Registration Number
EUCTR2010-020437-12-LT
Lead Sponsor
DermaTools Biotech GmbH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
120
Inclusion Criteria

·Gender: male/female (of non-childbearing potential defined as being amenorrhoeic for longer than 2 years with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms) (1)
·Age: from 18 to 80 years to be included (2)
·Diabetic foot ulcer diameter in between 1,5-3,5cm after débridement (if indicated) wound stage Wagner grade I or II, Armstrong stadium A-C (for Wagner-Armstrong-Classification see Appendix 1) (3)
·Other wounds with impaired healing, e.g. decubitus ulcer, arterial and/or venous leg ulcer, Charcot's foot or malum perforans, may be present in the same patient but shall not be selected as targets for the present study (4)
·Diabetes mellitus; HbA1c to be controlled (5)
·Adequate perfusion of lower leg as determined for instance by the ankle brachial pressure index (>0.5), or by a more precise method (e.g. TcPO2 > 30 mmHg, pelvic/leg angiography, duplex sonography in discretion of the
investigator) to exclude patients who require a revascularization therapy, examination results should be not older than 3 months (6)
·The patient must give written informed consent, after having been informed about benefits and potential risks of the trial, as well as details of the insurance taken out to cover the patients participating in the study (7)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 80

Exclusion Criteria

·Local antibiotic therapy of the target wounds selected for the study (1)
·Suspicion of bone infection or osteomyelitis affecting the area of target wound (2)*
·Severe peripheral arterial occlusive disease in the pelvic region or lower extremities (3)
·Vascular reconstruction or angioplasty less than 3 months ago or planned revascularization procedure (4)
·Inability or unwillingness to be fitted with appropriate shoe gear or an off-loading device (if required) (5)
·Clinically significant abnormal laboratory values except those typical for the underlying diseases mentioned in the inclusion criteria (6)
·Severe or uncontrolled heart disease (7)
·Severe renal failure treated with dialysis (8)
·Severe hepatic disease (9)
·Concurrent illness or a condition that may interfere with wound healing other those mentioned in the inclusion criteria (e. g. carcinoma, haematological disease, vasculitis, connective tissue disease, alcohol neuropathy; history of or current drug or alcohol abuse) (11)
·Previous radiation of the region of the target wounds selected for the study (12)
·Exposure of any systemic immunosuppressive or cytostatic therapy during the previous 30 days prior to the study, this refers also to any kind of glucocorticoids (13)
·Severe psychiatric or neurological disorder (14)
·Incapability of giving informed legal consent (15)
·Co-worker, student, relative or spouse of the investigator (16)
·Participation in the study already before (17)
·Participation in another experimental clinical trial during the previous 30 days prior to the present study (18)
·HbA1c >9,5% If the patient does not meet this inclusion criterion, randomisation may be delayed and screening visit may be repeated. (19)

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath